drugset / Trial / NCT01671020

Clinical Trials for Single Oral Dose of 60mg Fimasartan and Single IV Infusion of 30mg Fimasartan to Evaluate the Absolute Bioavailability of Kanarb® Tablet (Fimasartan) in Healthy Subjects

NCT01671020

Phase 1 Completed 16 enrolled Boryung Pharmaceutical Co., Ltd
RandomizedCrossoverOpen-label

Summary

Open-label, randomized, crossover clinical trials for single oral dose of 60mg fimasartan and single IV infusion of 30mg fimasartan to evaluate the absolute bioavailability of Kanarb® tablet (fimasartan) in healthy subjects

Timeline

Start
2012-06
Primary completion
2012-07
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fimasartan Small molecule 30 mg Oral
Comparator Fimasartan Small molecule 60 mg Oral

Indications

No indication recorded.